

PRODUCT INFORMATION

EUFLEXXA®

(1% sodium hyaluronate)

CONTENT

Each 1 ml of EUFLEXXA® contains:
Sodium hyaluronate 10 mg
Sodium chloride 8.5 mg
Disodium hydrogen phosphate dodecahydrate 0.56 mg
Sodium dihydrogen phosphate dihydrate 0.05 mg
Water for injection q.s.

DESCRIPTION

EUFLEXXA® is a viscoelastic, sterile solution of highly purified, high molecular weight (2.4-3.6 million daltons) hyaluronan (also known as sodium hyaluronate) in phosphate-buffered saline. EUFLEXXA® is a very highly purified product extracted from bacterial cells. It is a polysaccharide consisting of a repeating disaccharide of N-acetylglucosamine and sodium glucuronate, linked by alternating $\beta \rightarrow 1,3$ and $\beta \rightarrow 1,4$ glycosidic bonds.

INDICATION

EUFLEXXA® (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

CONTRAINDICATIONS

- Do not use EUFLEXXA® to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Do not use EUFLEXXA® to treat patients with knee joint infections, infections or skin disease in the area of the injection site.

WARNINGS

- Mixing of quaternary ammonium salts such as benzalkonium chloride with hyaluronan solutions results in formation of a precipitate.
EUFLEXXA® should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use disinfectants for skin preparation that contain quaternary ammonium salts.
- Do not inject intravascularly because intravascular injection may cause systemic adverse events.

PRECAUTIONS

GENERAL

- Patients having repeated exposure to EUFLEXXA® have the potential for an immune response; however, this has not been assessed in humans.
- Safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee has not been established.
- Remove any joint effusion before injecting.
- Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA®.
- Do not use after expiration date.
- Protect from light.
- Do not re-use—dispose of the syringe after use.
- Do not use if the blister package is opened or damaged.

Information for Patients

- Provide patients with a copy of the Patient Information prior to use.
- Transient pain and/or swelling of the injected joint may occur after intra-articular injection of EUFLEXXA®.
- As with any invasive joint procedure, it is recommended that the patient avoid any strenuous activities or prolonged (i.e., more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours following intra-articular injection.
- The safety of repeated treatment cycles of EUFLEXXA® has been established up to 1 year.

Use in Specific Populations

- **Pregnancy:** The safety and effectiveness of EUFLEXXA® have not been established in pregnant women.
- **Nursing Mothers:** It is not known if EUFLEXXA® is excreted in human milk. The safety and effectiveness of EUFLEXXA® have not been established in lactating women.
- **Children:** The safety and effectiveness of EUFLEXXA® have not been demonstrated in children.

ADVERSE REACTIONS

Adverse event information regarding the use of EUFLEXXA® as a treatment for pain in OA of the knee was available from two sources; a 12 week multicenter clinical trial conducted in Germany, and a 26 week multicenter clinical trial conducted in the US.

Reported Device-Related Adverse Events

The most common adverse event related to EUFLEXXA® injections reported in the clinical studies are the following:

- Arthralgia
- Back pain
- Pain in extremity
- Musculoskeletal pain
- Joint swelling

All adverse events related to EUFLEXXA injections reported in the tables 1, 2, 3 and 4.

Potential Adverse Events

The following adverse events are among those that may occur in association with intra-articular injections

- Arthralgia
- Joint swelling
- Joint effusion
- Injection site pain
- Arthritis

12 Week Multicenter Clinical Study

This clinical investigation was a prospective randomized, double blinded, active control (commercially available hyaluronan product) study conducted at 10 centers. Three hundred twenty-one patients were randomized into groups of equal size to receive either EUFLEXXA® (n=160) or the active control (n=161).

A total of 119 patients reported 196 adverse events; this number represents 54 (33.8%) of the EUFLEXXA® group and 65 (44.4%) of the active control group. There were no deaths reported during the study. Incidences of each event were similar for both groups, except for knee joint effusion, which was reported by 9 patients in the active control group and one patient in the EUFLEXXA® treatment group. Fifty-two adverse events were considered device-related. Table 1 lists the adverse events reported during this investigation.

Table 1. Incidence of Adverse Events Reported by >1% of Patients

Body System	ADE	Patients, n (%)	
		EUFLEXXA® (n = 160)	Active Control (n = 161)
Gastrointestinal disorders	Nausea	3 (1.88)	0
General disorders and administration site	Fatigue	2 (1.25)	0
Infections and infestations	Bronchitis	1 (0.63)	2 (1.24)
	Infection	2 (1.25)	0
Investigations	Blood pressure increased	6 (3.75)	1 (0.62)
Musculoskeletal, connective tissue and bone	Arthralgia	14 (8.75)	17 (10.6)
	Arthrosis	2 (1.25)	0
	Back pain	8 (5.00)	11 (6.83)
	Joint disorder	2 (1.25)	2 (1.24)
	Joint effusion	1 (0.63)	13 (8.07)
	Joint swelling	3 (1.88)	3 (1.86)
	Pain in limb	2 (1.25)	0
	Tendonitis	3 (1.88)	2 (1.24)
Nervous system disorders	Headache	1 (0.63)	3 (1.86)
	Paresthesia	2 (1.25)	1 (0.62)
Respiratory, thoracic and mediastinal	Rhinitis	5 (3.13)	7 (4.35)
Skin and subcutaneous tissue disorders	Erythema	0	2 (1.24)
	Pruritus	0	3 (1.86)
Vascular disorders	Phlebitis	0	2 (1.24)

A total of 160 patients received 478 injections of EUFLEXXA®. There were 27 reported adverse events considered to be related to EUFLEXXA® injections: arthralgia – 11 (6.9%); back pain – 1 (0.63%); blood pressure increase – 3 (1.88%); joint effusion – 1 (0.63%); joint swelling – 3 (1.88%); nausea – 1 (0.63%); paresthesia – 2 (1.25%); feeling of sickness of injection – 3 (1.88%); skin irritation – 1 (0.63%); tenderness in study knee – 1 (0.63%). Four adverse events were reported for the EUFLEXXA® group that the relationship to treatment was considered to be unknown: fatigue – 3 (1.88%); nausea – 1 (0.63%).

Table 2. Relationship of Adverse Effects to Treatment Groups That Were Considered to Be Treatment Related

Adverse Event	(EUFLEXXA®) (Number of Reports) n = 160	Commercially Available Hyaluronan Product (Number of Reports) n = 161
Arthralgia	11	9
Back pain	1	0
Baker's cyst	0	1
Blood pressure increase	3	0
Erythema	0	1
Inflammation localized	0	1
Joint effusion	1	9
Joint swelling	3	2
Nausea	1	0
Edema lower limb	0	1
Paresthesia	2	0
Pruritus	0	1
Sickness	3	0
Skin irritation	1	0
Tenderness	1	0
TOTAL	27	25

26 Week Multicenter Study

This was a multicenter, randomized, double-blind trial evaluating the efficacy and safety of EUFLEXXA®, as compared with saline, in subjects with chronic osteoarthritis of the knee followed by an open labeled safety extension study. The intervention consisted of three (3) weekly injections of study device into the target knee, with scheduled follow-up evaluations during the 26 weeks following the first injection. In the extension phase subjects received three (3) weekly injections of EUFLEXXA® into the target knee with follow-up evaluation up to 52 weeks. Table 3 shows the treatment-emergent adverse events by preferred term with an incidence of ≥ 2% among treatment groups.

Table 3: Treatment-Emergent Adverse Events by Preferred Term with an Incidence of ≥ 2% among the Treatment Groups (Safety Population)

System Organ Class Preferred Term	26 Week FLEXX Study (Core)			Extension Study Repeat Injection for 52 Weeks*
	All Treatments N = 588 n (%)	Saline N = 295 n (%)	EUFLEXXA® N = 293 n (%)	EUFLEXXA® N = 219 n (%)
Any TEAE	326 (55.4)	169 (57.3)	157 (53.6)	96 (43.8)
Musculoskeletal and connective tissue disorders				
Arthralgia	62 (10.5)	35 (11.9)	27 (9.2)	19 (8.7)
Back pain	23 (3.9)	11 (3.7)	12 (4.1)	6 (2.7)
Pain in extremity	13 (2.2)	10 (3.4)	3 (1.0)	3 (1.4)
Musculoskeletal pain	10 (1.7)	4 (1.4)	6 (2.0)	2 (0.9)
Osteoarthritis	9 (1.5)	7 (2.4)	2 (0.7)	0
Joint Swelling	8 (1.4)	4 (1.4)	4 (1.4)	6 (2.7)
Infections and infestations				
Upper respiratory tract infection	23 (3.9)	11 (3.7)	12 (4.1)	6 (2.7)
Nasopharyngitis	17 (2.9)	13 (4.4)	4 (1.4)	10 (4.6)
Sinusitis	16 (2.7)	10 (3.4)	6 (2.0)	5 (2.3)
Urinary tract infection	12 (2.0)	6 (2.0)	6 (2.0)	3 (1.4)
Injury, poisoning, and procedural complications				
Injury	17 (2.9)	9 (3.1)	8 (2.7)	9 (4.1)
Nervous system disorders				
Headache	17 (2.9)	11 (3.7)	6 (2.0)	3 (1.4)
Gastrointestinal disorders				
Diarrhea	14 (2.4)	2 (0.7)	12 (4.1)	3 (1.4)
Nausea	12 (2.0)	7 (2.4)	5 (1.7)	4 (1.8)
Respiratory, thoracic, and mediastinal disorders				
Cough	10 (1.7)	3 (1.0)	7 (2.4)	3 (1.4)
Vascular disorders				
Hypertension	18 (3.1)	5 (1.7)	13 (4.4)	1 (0.5)

*Treatment group for repeat study are for subjects who received EUFLEXXA® in both the core and extension (219 out of 433).

N = number of subjects in a given treatment group for the population analyzed; n = number of subjects reporting at least one adverse event within system organ class/preferred term; (%) = percentage of subjects based on N; TEAE = treatment-emergent adverse event.
 Note: An adverse event was counted as a TEAE if it was either not present at baseline (prior to the first dose of double-blind study device) or present at baseline but increased in severity during the treatment period.

During the initial randomization/treatment phase, 326 (55.4%) subjects in the safety population experienced 742 TEAEs. The proportion of subjects reporting TEAEs was generally similar in the EUFLEXXA® and saline groups (53.6% and 57.3%, respectively). The most common preferred term of TEAE was arthralgia (10.5% of all subjects). Thirty (5.1%) subjects experienced severe TEAEs, and the proportion with severe events was larger in the saline group (6.4%) than the EUFLEXXA® group (3.8%). Overall, 10.4% of subjects had TEAEs considered related to study device, with comparable proportions in each treatment group (9.9% and 10.8% for EUFLEXXA® and saline, respectively).

During the extension phase, 43.4% (188/433) of subjects reported 377 TEAEs. Of these 43.8% (96/219) subjects receiving repeated EUFLEXXA® reported 199 TEAEs. The most frequently reported preferred term in subjects formerly assigned to the core study EUFLEXXA® group were arthralgia (8.7%), nasopharyngitis (4.6%), injury (4.1%), upper respiratory tract infections (2.7%), joint swelling (2.7%), back pain (2.7%), and sinusitis (2.3%). Of these TEAEs 9 (4.1%) subjects had study drug related AEs classified as "Certain," "Probable," "Possible" or "Un-assessable." The most common related TEAEs were arthralgia (2.3%) and joint swelling (1.4%). Table 4 shows the Study Drug Related Treatment-Emergent Adverse Events by Preferred Term with an Incidence of > 1 among Treatment Groups (Safety Population).

Table 4: Study Drug Related Treatment-Emergent Adverse Events by Preferred Term with an Incidence of ≥ 1 among Treatment Groups (Safety Population)

System Organ Class Preferred Term	26 Week FLEXX Study (Core)			Extension Study Repeat Injection for 52 Weeks*
	All Treatments N = 588 n (%)	Saline N = 295 n (%)	EUFLEXXA® N = 293 n (%)	EUFLEXXA® N = 219 n (%)
Any related TEAEs	61 (10.4)	32 (10.8)	29 (9.9)	9 (4.1)
Musculoskeletal and connective tissue disorders				
Arthralgia	23 (3.9)	13 (4.4)	10 (3.4)	5 (2.3)
Joint Swelling	3 (0.5)	2 (0.7)	1 (0.3)	3 (1.4)
Pain in extremity	3 (0.5)	3 (1)	0	0
Skin and subcutaneous tissue disorders				
Erythema	5 (0.9)	3 (1)	2 (0.7)	0

*TEAEs are for subjects who received EUFLEXXA® in both the core and extension (219 out of 433).
 N = number of subjects in a given treatment group for the population analyzed; n = number of subjects reporting at least 1 AE within system organ class/preferred term; (%) = percentage of subjects based on N; TEAE = treatment-emergent adverse event.
 Note: Related AEs are AEs with study drug relationship classified as "Certain," "Probable," "Possible" or "Un-assessable."

Twenty-three serious TEAEs were reported in 19 (3.2%) subjects during the study: 10 (3.4%) subjects in the EUFLEXXA® group and 9 (3.1%) subjects in the saline group. One of these events was considered related to the study device (increased redness of the left knee joint in the EUFLEXXA® group). Eight (1.4%) subjects had 9 TEAEs leading to discontinuation: 3 (1.0%) subjects in the EUFLEXXA® group and 5 (1.7%) subjects in the saline group.

Twelve (2.8%) subjects reported 20 serious TEAEs during the extension phase. Six of these subjects had received EUFLEXXA® during the core study. None of the serious TEAEs was considered related to study device, and all resolved. Two (0.5%) subjects had TEAEs leading to discontinuation from the study, 1 of whom received EUFLEXXA® during the core study; both subjects had events that were considered unrelated to study device.

Two subjects on saline experienced joint effusion. There were no reports of joint effusion among subjects receiving EUFLEXXA® during the core and extension phase.

CLINICAL STUDIES

12 Week Multicenter Clinical Trial

The safety and effectiveness of EUFLEXXA® as a treatment for pain in OA of the knee was investigated in a multicenter clinical trial conducted in Germany.

Study Design

The clinical investigation was a prospective randomized, double blinded, active control (commercially available hyaluronan) study conducted at 10 centers in Germany. A total of 321 patients with stage 2 – 3 osteoarthritis of the knee according to the Kellgren and Lawrence grading system, meeting the Altman Criteria for Classification of Idiopathic Osteoarthritis of the knee, and scoring an average score of 41 – 80 mm on the WOMAC VAS pain index were randomized into groups of equal size to receive either EUFLEXXA® (160 patients) or the active control (161 patients).

Patient Population and Demographics

The demographics of trial participants were comparable across treatment groups with regard to age, gender, Kellgren and Lawrence grading system, stiffness, crepitus, bony enlargement, and no palpable warmth. Table 5 lists the demographics of the patient population.

Table 5. Patient Baseline Characteristics

Parameter	Number of Patients (%)	
	EUFLEXXA®	Active Control
† Kellgren and Lawrence Grading System		
Definite osteophytes (Stage 2)	88 (55.0%)	84 (52.2%)
Moderate multiple osteophytes (Stage 3)	72 (45.0%)	77 (47.8%)
Study Knee		
Left	73 (45.6%)	80 (49.7%)
Right	87 (54.4%)	81 (50.3%)
Age (n = number of patients)	62.7 ± 7.5 (160)	63.7 ± 7.3 (161)
Female (n)	62.9 ± 7.9 (99)	64.3 ± 7.3 (108)
Male (n)	62.5 ± 6.8 (61)	62.5 ± 7.3 (53)
Osteoarthritis duration		
Study knee (months prior to enrollment)	57.1 ± 45.9	60.7 ± 53.5
Radiological diagnosis		
Study Knee (months prior to enrollment)	3.9 ± 3.8	4.4 ± 6.4
‡ Altman Criteria		
Knee pain	160 (100%)	161 (100%)
Stiffness < 30 minutes	151 (94.4%)	151 (93.8%)
Crepitus	154 (96.3%)	159 (98.8%)
Bony tenderness	134 (83.8%)	145 (90.1%)
Bony enlargement	72 (45.0%)	76 (47.2%)
No palpable warmth	153 (95.6%)	149 (92.5%)
No palpable warmth	153 (95.6%)	149 (92.5%)

† Kellgren and Lawrence (Ann Rheum Dis 1957;(16):494-501): Based on radiological findings, osteoarthritis stages were defined as follows: 0 = normal, 1 = doubtful narrowing of joint space and possible osteophytic lipping, 2 = definite osteophytes and possible narrowing of joint space, 3 = moderate multiple osteophytes and definite narrowing of joint space, some sclerosis and possible deformity of bone contour, 4 = large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone contour.

‡ Altman, et al., (Arthritis and Rheumatism 1986;29(8):1039-1049): Clinical criteria for classification of idiopathic osteoarthritis (OA) of the knee were defined as follows:

Knee pain and at least 3 of the following 6 parameters: Age > 50 years, Stiffness < 30 minutes, Crepitus, Bony tenderness, Bony enlargement, No palpable warmth

Clinical Results

For this trial, the main performance analysis for determining non-inferiority was determined using the improvement in the average of the five patient's self-evaluation pain parameters measured by the VAS WOMAC index at week 12 from baseline. This analysis was performed for both the intent-to-treat population, (i.e., every subject who received the injection), and the evaluable population, (i.e., those subjects who had average pain scores of 41-80 allowing only one parameter to be below 20 or above 80 at both the pre-screening visit and visit 1). For those patients who dropped out of the study before week 12, the last evaluation was used. For those patients who requested NSAID or analgesic during the study, the last evaluation before start of NSAID/analgesic was used for the analysis. The results indicate that the effect of EUFLEXXA® on pain relief was not inferior to that of a commercially available hyaluronan.

Table 6. Changes from Baseline to Last Visit in Overall Pain Score (primary end point, average of five pain scores)

	EUFLEXXA®		Active Control (commercially available hyaluronan)		Standard Deviation	P value (non-inferiority)
	N	Change from Baseline (mm)	N	Change from Baseline (mm)		
ITT – patient	160	29.9	161	28.4	21	0.0032

26 Week Multicenter Clinical Trial

This was a multicenter, randomized, double-blind trial evaluating the efficacy and safety of EUFLEXXA® as compared to saline comparator in subjects with chronic osteoarthritis of the knee. The intervention consisted of three weekly injections into the target knee with evaluations from baseline through Week 26 (1, 2, 3, 6, 12, 18, and 26). The primary objective was to demonstrate superiority over saline comparator from baseline to Week 26 using the pain level reported following a 50 foot walk test, measured by 100 mm visual analog scale. The following secondary endpoints were also evaluated: OASRSI responder rate at Week 12 and Week 26; WOMAC pain, disability, and joint stiffness score changes from baseline to Week 12 and 26; and change in Patient Global Assessment from baseline to Week 12 and Week 26.

Patient Population and Demographics

A total of 821 subjects were screened for the study, and 588 subjects were randomized. Approximately 88% of the randomized subjects completed the study, with similar proportions completing in each treatment group. Sixty-eight (11.6%) subjects discontinued the randomization/treatment phase prematurely: 34 (11.5%) in the saline group and 34 (11.6%) in the EUFLEXXA® group. The most common reasons for discontinuation were the subject's withdrawing consent 25 (4.3%) and AEs 17 (2.9%). A total of 433 (73.6%) subjects entered the open-label extension study.

Clinical Results

Primary endpoint

In the primary efficacy analysis, the EUFLEXXA® group showed a larger mean decrease in pain scores on the 50-foot walk test from baseline to Week 26 than the saline group: -25.7 (28.85) mm versus -18.5 (32.53) mm, respectively. The group difference in least squares mean change from baseline of -6.6 mm (95% CI = -10.8 to -2.5 mm) was statistically significant (p-value = 0.002). Figure 1 depicts the adjusted mean change in pain scores on 50-foot walk test from baseline to week 26 (ITT Population).

Table 7. The Adjusted Mean Change in Pain Scores on 50-foot Walk Test from Baseline to Week 26 (ITT^a Population).

	Change from Baseline at Week 26		Difference in Changes (EUFLEXXA - Saline) from Baseline ^{b,c,d}	2-Sided 95% Lower and Upper Bound of Confidence Interval of the Difference ^d in Changes ^c	2-Sided P-Value ^c
	Saline (n=295) (SD)	EUFLEXXA (n=291) (SD)			
50-foot walk test, measured on a 100mm horizontal VAS score improvement at 26 weeks	-18.5 (32.53)	-25.7 (28.85)	-6.6 mm	-10.8, -2.5	0.002


^a ITT= Intent to Treat

^b Negative (-) values favor EUFLEXXA.

^c The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score improvement at 26 weeks, with a weekly injection of EUFLEXXA for 3 weeks.

^d difference = least squares mean difference

Figure 1 Adjusted Mean Change in Pain Scores on 50-foot Walk Test from Baseline to Week 26 (ITT Population)



Secondary Endpoints

Table 8. OARSi Responder Rates Using 50-foot Walk Test (ITT)

Visit Response/Statistics	Saline N=295	EUFLEXXA N=291	All Treatments N=586	Overall Comparison (2-sided 95% Lower and Upper Bound of Confidence Interval of Odds Ratio) ^c
Week 12				
No. of subjects with data	274	263	537	
Yes-n (%)	167 (60.9)	173 (65.8)	340 (63.3)	
No-n (%)	107 (39.1)	90 (34.2)	197 (36.7)	
Odds ratio ^a (95% CI)				1.3 (0.9, 1.8)
P-value				0.202
Week 26				
No. of subjects with data	264	254	518	
Yes-n (%)	155 (58.7)	169 (66.5)	324 (62.5)	
No-n (%)	109 (41.3)	85 (33.5)	194 (37.5)	

Odds ratio ^b (95%CI)				1.4 (1.0, 2.1)
P-value				0.047

OARS = Osteoarthritis Research Society International; ITT = intent-to-treat; N = number of subjects in a given treatment group for the population analyzed; n = number of subjects; (%) = percentage of subjects based on N; CI = confidence interval.

Note: The p-value for the odds ratio corresponds to the Wald chi-square test for EUFLEXXA versus saline with respect to OARS responder rates from a logistic regression adjusting for treatment group and study center.

Note: A subject was considered a responder if there was high improvement in pain or function >50% and absolute change >20 mm or improvement in at least two of the three following categories: pain >20% and absolute change >10 mm, function >20% and absolute change >10 mm, and/or Patient Global Assessment >20% and absolute change >10.

^{a, b, e} (Log Odds Ratio) = 1.27 for 12 weeks and 1.4 for 26 weeks, based on a logistic regression model

$$(\text{Log Odds Ratio}) = \log_e \left[\frac{\text{probability}(\text{responder}) / \text{probability}(\text{non-responder})_{\text{EUFLEXXA}}}{\text{probability}(\text{responder}) / \text{probability}(\text{non-responder})_{\text{saline}}} \right]$$

^c When odds ratio >1, $[\text{probability}(\text{responder}) / \text{probability}(\text{non-responder})]_{\text{EUFLEXXA}} > [\text{probability}(\text{responder}) / \text{probability}(\text{non-responder})]_{\text{saline}}$

Table 9. Other Secondary Endpoints at 26 Weeks for ITT (n=291)

	Change from Baseline at Week 26		The Difference ^d in Changes (EUFLEXXA - Saline) from the Baseline ^b	2-Sided Test P-Value ^a
	Saline (SD) (n=295)	EUFLEXXA (SD) (n=291)		
WOMAC C ^e (disability)	-14.6 (25.79)	-19.5 (24.68)	-4.3 mm	0.019
WOMAC B (joint stiffness)	-15.4 (29.33)	-19.6 (31.27)	-3.8 mm	0.075
WOMAC A (pain)	-16.3 (26.82)	-19.2 (26.81)	-3.3 mm	0.085
Patient Global Assessment	-17.8 (28.82)	-22 (30.38)	-4.5 mm	0.035

Note: The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline.

^a P-values are not adjusted for the multiplicity.

^b Negative (-) values for WOMAC C and Patient Global Assessment are in favor of EUFLEXXA.

^c The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip. WOMAC Pain Scale is 100mm.

^d difference=least square mean difference

No significant treatment group differences were observed in the change in number of study-specific acetaminophen tablets used per week or in the proportion of subjects who were pain free at Week 26 or last visit.

DETAILED DEVICE DESCRIPTION

Each syringe of EUFLEXXA[®] contains:
 Sodium hyaluronate 20 mg
 Sodium chloride 17 mg
 Disodium hydrogen phosphate dodecahydrate 1.12 mg
 Sodium dihydrogen phosphate dihydrate 0.1 mg
 Water for injection q.s.

INTERACTIONS

None currently known

HOW SUPPLIED

EUFLEXXA® is supplied in 2.25 ml nominal volume, disposable, pre-filled glass syringes containing 2 ml of EUFLEXXA®. Only the contents of the syringe are sterile. EUFLEXXA® is nonpyrogenic.

This product is latex-free.

Product Number: 55566-4100-1

3 disposable syringes per carton

SHELF LIFE

18 months

STORAGE INSTRUCTIONS

Store at 2°-25°C (36°-77°F). Protect from light. Do not freeze. Remove from refrigeration at least 20-30 minutes before use.

CAUTION

Federal law restricts this device to sale by or on the order of a physician.

DIRECTIONS FOR USE

1. Each package of EUFLEXXA® is manufactured using aseptic filling techniques. Do not use if the blister package is opened or damaged.
2. Remove joint effusion, if present.
3. Peel off the blister Tyvek backing (The syringe should be used immediately after the individual syringe blister is opened).
4. While holding the blister open side down, bend the blister and allow the syringe to fall gently onto the clean surface. Alternatively, hold the blister open side up and bend back the blister until the barrel's luer end is exposed. Gripping the luer end of the barrel, remove the syringe from the blister. **Do not remove the syringe from the plunger end.**
5. Remove the tip cap from the syringe and attach an appropriately sized sterile needle, for example 17 to 21 mm gauge.

Attention: Do not apply pressure to the plunger rod while the needle is being affixed. Verify that the needle is properly locked to the Luer Lock Adaptor (LLA). Do not overtighten the LLA; this can lead to loosening of the LLA from the barrel.

6. Apply gentle pressure to the plunger in order to expel air from the syringe needle and to verify that the syringe is operating properly.
7. The syringe is ready for use.
8. Inject intra-articularly into the knee synovial capsule using strict aseptic injection procedures. Inject the full syringe contents, 2 ml into one knee only. If treatment is being administered to both knees, use a separate syringe for each knee. Discard any unused EUFLEXXA®.
9. For single use only. Do not resterilize.
10. Store at 2°-25°C (36°-77°F). Protect from light. Do not freeze. If refrigerated, remove from refrigeration at least 20-30 minutes before use.
11. A dose of 2 ml is injected intra-articularly into the affected knee at weekly intervals for three weeks, for a total of three injections.

Toll free number for providers and patients to call with questions:
1-888-FERRING (1-888-337-7464).

MANUFACTURED FOR:

(FERRING LOGO)

FERRING PHARMACEUTICALS INC.

PARSIPPANY, NJ 07054

MANUFACTURED BY:
Bio-Technology General (Israel) Ltd.
Be'er Tuvia, Kiryat Malachi 83104, Israel

Product Code: 55566-4100-1
6122-10